Cancer Radiotherapie最新文献

{"title":"Hypofractionated radiotherapy for localized prostate cancer: From phase III evidence to real-world outcomes with or without elective pelvic nodal irradiation","authors":"Charles Raynaud,&nbsp;Diane Jornet,&nbsp;Sophie Guillerm,&nbsp;Pierre Mongiat-Artus,&nbsp;Evangelos Xylinas,&nbsp;Jean-François Hermieu,&nbsp;François Desgrandchamps,&nbsp;Christophe Hennequin,&nbsp;Laurent Quéro","doi":"10.1016/j.canrad.2026.104858","DOIUrl":"10.1016/j.canrad.2026.104858","url":null,"abstract":"<div><h3>Purpose</h3><div>Hypofractionated radiotherapy is a standard treatment for localized prostate cancer, supported by phase III trials showing non-inferiority versus conventional fractionation. However, most trials excluded elective pelvic lymph node irradiation, so evidence remains limited when pelvic nodes are treated. The primary objective of this study was to compare clinical outcomes and toxicity profiles between normofractionated radiotherapy and moderately hypofractionated radiotherapy.</div></div><div><h3>Material and methods</h3><div>We performed a narrative review of phase III trials evaluating moderate or ultra-hypofractionated radiotherapy, then conducted a retrospective single-institution analysis comparing conventional fractionation (delivering 80<!--> <!-->Gy in 40 fractions) with moderate hypofractionation (delivering 72.5<!--> <!-->Gy in 29 fractions), with or without elective pelvic lymph node irradiation. The primary endpoint was disease-free survival. Secondary endpoints were overall survival and acute and late genitourinary and gastrointestinal toxicity.</div></div><div><h3>Results</h3><div>Eleven phase III trials were identified, confirming non-inferiority of moderate hypofractionation for prostate-only irradiation. In our cohort of 156 patients (76 treated with conventional fractionation and 80 with moderate hypofractionation), half received elective pelvic lymph node irradiation, and three quarters received androgen deprivation therapy. After a median follow-up of 69 months, 5-year disease-free survival was 85 % with conventional fractionation and 84 % with moderate hypofractionation, with similar five-year overall survival (88 % and 84 %). Grade 2 or higher acute genitourinary toxicity was more frequent with moderate hypofractionation, whereas late genitourinary and gastrointestinal toxicities were comparable.</div></div><div><h3>Conclusions</h3><div>Moderate hypofractionation achieved disease control similar to conventional fractionation with acceptable toxicity, including in patients receiving elective pelvic lymph node irradiation. These findings support extension of moderate hypofractionation to patients requiring pelvic treatment and the need for prospective validation and integration with androgen deprivation therapy and stereotactic radiotherapy.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 4","pages":"Article 104858"},"PeriodicalIF":1.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149032228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiation-induced oral mucositis: Correlation between clinician-assessed WHO grades and patient-reported outcomes, an exploratory prospective observational pilot study","authors":"Priya Kumar,&nbsp;Kuldeep Singh,&nbsp;Jeyaseelan Augustine,&nbsp;Aadithya B. Urs","doi":"10.1016/j.canrad.2026.104855","DOIUrl":"10.1016/j.canrad.2026.104855","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;Oral mucositis is a frequent, dose-limiting toxicity of chemoradiotherapy of head and neck cancer. Clinician-based grading such as the world health organization mucositis scale provides objective assessment of visible lesions, but patient-reported oral mucositis symptom scale capture the subjective functional impact, which may not always correspond with clinical findings. This pilot study examined the association between clinician grading and patient-reported measures and explored differences between benzydamine and bicarbonate rinses.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Oral mucositis is a frequent, dose-limiting toxicity of chemoradiotherapy of head and neck cancer. Clinician-based grading such as the world health organization mucositis scale provides objective assessment of visible lesions, but patient-reported oral mucositis symptom scale capture the subjective functional impact, which may not always correspond with clinical findings. This pilot study examined the association between clinician grading and patient-reported measures and explored differences between benzydamine and bicarbonate rinses.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Patients and methods&lt;/h3&gt;&lt;div&gt;Twenty patients with head and neck cancer receiving definitive chemoradiotherapy were enrolled; ten received benzydamine and ten bicarbonate rinses. Weekly world health organization mucositis grading and patient-reported oral mucositis symptoms (10-item Visual Analogue Scale assessing pain, speech, eating, swallowing, and taste) were recorded across seven weeks. Spearman's correlation was performed, and descriptive comparisons were made between rinse groups.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Twenty patients with head and neck cancer receiving definitive chemoradiotherapy were enrolled; ten received benzydamine and ten bicarbonate rinses. Weekly world health organization mucositis grading and patient-reported oral mucositis symptoms (10-item Visual Analogue Scale assessing pain, speech, eating, swallowing, and taste) were recorded across seven weeks. Spearman's correlation was performed, and descriptive comparisons were made between rinse groups.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;All patients developed mucositis by week 7. Peak severity ranged from grade 1 to grade 4, with most patients reaching grade 3. Median onset of ulcerative mucositis (grade 2 or worse) was week 3. Patient-reported oral mucositis symptoms correlated with World Health Organization grades (Spearman's ρ&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.72, &lt;em&gt;p&lt;/em&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;0.01) and increased with ulcerative progression. Taste alteration and difficulty eating solids were most affected domains. Some patients reported symptoms despite absent visible lesions. No significant differences were found between the two rinse groups.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;All patients developed mucositis by week 7. Peak severity ranged from grade 1 to grade 4, with most patients reaching grade 3. Median onset of ulcerative mucositis (grade 2 or worse) was week 3. Patient-reported oral mucositis s","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 3","pages":"Article 104855"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148690434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Organs at risk radiation dose constraints: 2025 update","authors":"Georges Noël,&nbsp;Antoine Ailloud,&nbsp;Véronique Vendrely,&nbsp;Cyrus Chargari,&nbsp;Jonathan Khalifa,&nbsp;Yoann Pointreau,&nbsp;Delphine Antoni,&nbsp;Amina Lekhal,&nbsp;Igor Latorzeff","doi":"10.1016/j.canrad.2026.104833","DOIUrl":"10.1016/j.canrad.2026.104833","url":null,"abstract":"<div><div>We present the updated recommendations from the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology) regarding radiation dose constraints for organs at risk in adult patients, with the aim of supporting clinical decision-making in contemporary radiotherapy practice. These guidelines address a wide range of clinical scenarios, including normofractionation, hypofractionation, stereotactic radiotherapy, and reirradiation. Dose constraints are essential to ensure both the safety and efficacy of radiotherapy, especially with the growing use of advanced techniques such as intensity-modulated radiotherapy and stereotactic body radiotherapy. However, given the wide range of existing dose constraints and the lack of harmonization across different practices, this work aims to provide a unified and updated framework adapted to modern radiotherapy techniques. Moreover, many of these constraints are still based on data derived from three-dimensional conformal radiotherapy, which necessitates cautious application when extrapolated to more advanced techniques. Clinical judgment remains crucial, particularly in complex cases such as re-irradiation or treatments using altered fractionation schedules. These updated consensus aim to provide a practical and evidence-based framework to help radiation oncologists and medical physicists minimize the risk of toxicity to normal tissues. By consolidating and adapting current knowledge to modern radiotherapy techniques, they serve as a useful tool in daily clinical practice.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 3","pages":"Article 104833"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148690441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to “Successful identification and management of a stroke-like migraine attacks after radiation therapy syndrome occurring 36 years after cranial irradiation” [Cancer Radiother 29 (2025) 104618]","authors":"Louisien Lebrun,&nbsp;Dario Di Perri,&nbsp;Vincent Marneffe,&nbsp;Jean-Marc Raymackers","doi":"10.1016/j.canrad.2026.104853","DOIUrl":"10.1016/j.canrad.2026.104853","url":null,"abstract":"","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 3","pages":"Article 104853"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148690475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative study of interstitial brachytherapy and intensity-modulated radiotherapy as tumour bed boost after conservative surgery for breast cancer: Toxicity and cosmetic outcomes","authors":"Ankita Pandey,&nbsp;Uday Pratap Shahi,&nbsp;Laxman Pandey,&nbsp;Shreya Singh,&nbsp;Lalit Mohan Aggarwal,&nbsp;Ritusha Mishra,&nbsp;Himanshu Mishra","doi":"10.1016/j.canrad.2026.104834","DOIUrl":"10.1016/j.canrad.2026.104834","url":null,"abstract":"<div><h3>Introduction</h3><div>Radiotherapy improves survival of patients who underwent breast-conserving surgery. Tumour bed boost further improves the local control that can be delivered by interstitial brachytherapy, electron beam or X-ray photon beam therapy (external beam radiotherapy). The aim of the study was to compare cosmetic outcome and the factors affecting it after interstitial brachytherapy or external beam radiotherapy.</div></div><div><h3>Materials and methods</h3><div>Sixty patients with infiltrating ductal carcinoma who underwent breast conserving surgery were prospectively enrolled and treated by electron or X-ray photon beams to a total dose of 40<!--> <!-->Gy delivered in 15 fractions followed by tumour bed boost by interstitial brachytherapy (<em>n</em> <!-->=<!--> <!-->30) or external beam radiotherapy (<em>n</em> <!-->=<!--> <!-->30) to a dose of 14<!--> <!-->Gy delivered in four fractions. Both the groups were compared in terms of cosmesis, acute toxicity, late toxicity, dosimetry and survival.</div></div><div><h3>Results</h3><div>Median follow up period of the cohort was 56 months (range: 50–63<!--> <!-->months). There was no significant difference in the two groups in terms of toxicity and cosmetic outcome. Excellent/good cosmesis was seen in 85 % of total patients. Late skin toxicity was significantly lower in the group receiving interstitial brachytherapy. Doses to the normal structures such as heart and skin were significantly lower in patients who had brachytherapy. Using univariate analysis, tumour location (central region), use of neoadjuvant chemotherapy, vertical nipple deviation of more than 2<!--> <!-->cm and grade 3 skin induration were found to be significantly associated with fair/poor cosmetic outcome.</div></div><div><h3>Conclusion</h3><div>Tumour bed boost by external beam radiotherapy or interstitial brachytherapy provide equivalent result in terms of cosmesis. Interstitial brachytherapy has an edge over external beam radiotherapy in reducing skin doses resulting in decreased incidence of higher grade of late skin toxicity.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 3","pages":"Article 104834"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148383372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The place of radiotherapy in the treatment of inflammatory breast cancer: Practical questions and responses","authors":"Pierre Loap,&nbsp;Youlia Kirova","doi":"10.1016/j.canrad.2026.104857","DOIUrl":"10.1016/j.canrad.2026.104857","url":null,"abstract":"<div><div>Inflammatory breast cancer represents a rare and aggressive form of locally advanced breast cancer with distinct biological characteristics requiring specialized treatment approaches. Despite its clinical importance, standardized radiotherapy guidelines for inflammatory breast cancer management remain limited, and these patients are often underrepresented in clinical trials. This review aims to provide some practical radiotherapy recommendations for inflammatory breast cancer by integrating data from prospective clinical trials, population studies, and emerging genomic insights. The purpose is to establish clear therapeutic strategies that distinguish between chemosensitive and chemorefractory tumours, optimize dose fractionation and target volume definition, and provide guidance on combination with systemic therapies. These recommendations seek to improve clinical outcomes while avoiding inappropriate therapeutic de-escalation in this high-risk population requiring multidisciplinary expert discussions.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 3","pages":"Article 104857"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148690513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survey on the radiotherapy dosimetrist workforce in France: Present state and perspectives","authors":"Ève Focheux,&nbsp;Nathalie Hervé,&nbsp;Laure Parent,&nbsp;Ahmed Hadj Henni","doi":"10.1016/j.canrad.2026.104856","DOIUrl":"10.1016/j.canrad.2026.104856","url":null,"abstract":"<div><h3>Purpose</h3><div>The purpose of the study was to give an overview of the radiotherapy dosimetrist workforce in France, to provide quantitative indicators that can support actions or decisions aimed at better recognizing this profession in France.</div></div><div><h3>Materials and methods</h3><div>A survey was addressed to dosimetrists working in France (metropolitan France and overseas departments and territories) from April to May 2023. This survey covered four themes: (1) workplaces, staffing levels, and demographic data; (2) tasks performed; (3) training and status; (4) respondents’ expectations.</div></div><div><h3>Results</h3><div>A total of 239 people completed all or parts of the survey. Seventy-five percents of respondents were part of a team of at least three dosimetrists. Ninety percents of participants were under 50 years old and 75 % had more than 5 years of experience. A majority (61 %) of respondents reported to only perform treatment planning tasks. Apart from this, image fusion (75 %) and patient quality controls (54 %) were predominant. Before being dosimetrists, 54 % of respondents had been radiation therapy technologists. Fifty-six percents held a dosimetrist diploma. For 36 % of participants, salary grids differed within the same centre.</div></div><div><h3>Conclusion</h3><div>This is the first survey to provide an overview of the dosimetrist profession in France. It underlines a wide variety of career paths, profiles, and statuses. This situation highlights the need to raise awareness on this profession in order to guarantee the quality and safety of radiotherapy care. A French version of this article is available as supplementary material.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 3","pages":"Article 104856"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148690464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term control after stereotactic body radiotherapy for perineal recurrence of prostate cancer after radical prostatectomy and radiotherapy: A case report and review of the literature","authors":"Khadija Khouz,&nbsp;Khaoula Laabid,&nbsp;Paul Archer,&nbsp;Thomas Lacornerie,&nbsp;David Pasquier","doi":"10.1016/j.canrad.2026.104854","DOIUrl":"10.1016/j.canrad.2026.104854","url":null,"abstract":"<div><div>In this article, we report a case of perineal recurrence of prostate cancer occurring 9 years after postoperative radiotherapy following radical prostatectomy for localized prostate cancer. We describe the use of stereotactic body radiotherapy as a potential ablative treatment. Pelvic magnetic resonance imaging identified an 8-mm lesion located below the penile root on the left side, which was distinct from the prostatectomy site. Recurrence was proven by biopsy. Stereotactic body radiotherapy delivered 36<!--> <!-->Gy in six fractions every other day. The patient showed no recurrence or toxicity by 55 months of follow-up. To the best of our knowledge, this is the first reported case of perineal recurrence successfully treated using stereotactic body radiotherapy.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 3","pages":"Article 104854"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148727444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contribution of fluorodeoxyglucose positron-emission tomography combined with magnetic resonance imaging for differential diagnosis between radionecrosis and recurrence of treated brain metastasis","authors":"Darejan Bessac,&nbsp;Ashjan Kaseb,&nbsp;Seyyid Baloglu,&nbsp;Julien Todeschi,&nbsp;Georges Noël,&nbsp;Izzie Jacques Namer,&nbsp;Caroline Bund","doi":"10.1016/j.canrad.2026.104836","DOIUrl":"10.1016/j.canrad.2026.104836","url":null,"abstract":"<div><h3>Purpose</h3><div>Differentiating between changes after radiotherapy and radionecrosis during the follow-up of brain metastasis remains challenging. Hybrid positron-emission tomography/magnetic resonance imaging is a relatively novel imaging modality that integrates advanced magnetic resonance imaging sequences with metabolic data from positron-emission tomography. This study ailed to evaluate retrospectively the contribution of hybrid (¹⁸F)-fluorodeoxyglucose positron-emission tomography/magnetic resonance imaging in distinguishing radionecrosis from recurrent cerebral metastatis, comparing the diagnosis performance of (¹⁸F)-fluorodeoxyglucose positron-emission tomography and magnetic resonance imaging independently, without relying clinical or prior imaging data.</div></div><div><h3>Patients and methods</h3><div>Over a one-year period, we included 72 patients with brain metastases undergoing evaluation for differential diagnosis between recurrence and radionecrosis. Two senior nuclear medicine physicians and two senior radiologists independently analysed positron-emission tomography and magnetic resonance images. For semi-quantitative positron-emission tomography, analysis maximum standardized uptake value was measured at 30<!--> <!-->min and 4<!--> <!-->h postinjection and retention indices were calculated. Reading correlations between physicians was assessed using Cohen's Kappa coefficients. Clinical and imaging follow-up, considered the gold standard, was used to classify the lesion. For discordant cases, a joint interdisciplinary reading was conducted.</div></div><div><h3>Results</h3><div>A total of 142 treated brain metastases from 90 hybrid (¹⁸F)-fluorodeoxyglucose positron-emission tomography/magnetic resonance imaging scans of 72 patients were analysed. Based on the gold standard for diagnosis, the 142 lesions were categorized into two groups: 47 recurrences and 95 cases of radionecrosis. The sensibility and sensitivity of hybrid (¹⁸F)-fluorodeoxyglucose positron-emission tomography/magnetic resonance imaging were 97.9 and 100 %, respectively, outperforming both magnetic resonance imaging and positron-emission tomography alone.</div></div><div><h3>Discussion</h3><div>Dual time-point (¹⁸F)-fluorodeoxyglucose positron-emission tomography, with retention index calculation, shows significant in differentiating radionecrosis from recurrence. Technological advancements, such as hybrid positron-emission tomography/magnetic resonance imaging, enhance diagnostic accuracy in substantial patients’ cohorts. Further studies incorporating histological confirmation as the gold standard is warranted to validate these findings.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 3","pages":"Article 104836"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148407483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficiency and equity in radiotherapy accessibility and availability in France","authors":"David Ali,&nbsp;Vincent Marchesi,&nbsp;Albert Lisbona,&nbsp;Isabelle Choudat","doi":"10.1016/j.canrad.2026.104835","DOIUrl":"10.1016/j.canrad.2026.104835","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose of the study&lt;/h3&gt;&lt;div&gt;In France, while radiotherapy is primarily covered by national health insurance, disparities in access may persist. These disparities can be influenced by geographic location, leading to variations in travel time to the nearest radiotherapy unit, the number of accessible radiotherapy units within a reasonable commute, the availability of specific treatments such as brachytherapy, and the resource density within accessible radiotherapy units. This study aimed to assess the accessibility and availability of radiotherapy across France, identifying potential inequities among the population based on home location and regional mean income.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Material and methods&lt;/h3&gt;&lt;div&gt;The study covered metropolitan France (including Corsica) and the French overseas departments/territories of Guadeloupe, Martinique, and Réunion, using the &lt;em&gt;commune&lt;/em&gt; (municipality) and Paris/Marseille/Lyon &lt;em&gt;arrondissements&lt;/em&gt; (city districts; treated as separate &lt;em&gt;communes&lt;/em&gt;) as the geographic unit. For each department, annual sex-specific cancer incidence (2007–2014) was applied proportionally to &lt;em&gt;commune&lt;/em&gt; populations to estimate the number of patients undergoing radiotherapy, with the scaling coefficient derived from France-wide radiotherapy volumes in 2022. Geographic accessibility was quantified by calculating road and public-transport travel times from each &lt;em&gt;commune&lt;/em&gt;'s main city to all radiotherapy units, using Haversine-based candidate selection (up to 70&lt;!--&gt; &lt;!--&gt;km, extended to 100&lt;!--&gt; &lt;!--&gt;km) and Google Maps/La Poste (French postal service) validation; a radiotherapy unit was considered accessible for external beam radiotherapy, stereotactic body radiotherapy, and brachytherapy if best transportation time was less than 45&lt;!--&gt; &lt;!--&gt;min, 60&lt;!--&gt; &lt;!--&gt;min, and 90&lt;!--&gt; &lt;!--&gt;min, respectively. Availability was summarized using population-weighted efficiency (mean) and equity (dispersion via SD/IQR/D9/D1) across &lt;em&gt;communes&lt;/em&gt;, with &lt;em&gt;commune&lt;/em&gt;-level availability metrics derived from accessible radiotherapy units (averaged when multiple were accessible; otherwise from the closest), and no statistical testing performed because all French &lt;em&gt;communes&lt;/em&gt; were analysed.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Ninety percent of the study population had access to at least one radiotherapy unit within 45&lt;!--&gt; &lt;!--&gt;min of travel (one-way). Forty percent had access by public transportation within 45&lt;!--&gt; &lt;!--&gt;min. Two-thirds had access to at least two radiotherapy units within 45&lt;!--&gt; &lt;!--&gt;min. Excluding head and neck brachytherapy, 40 % of the population had access to all treatment modalities (external beam radiotherapy, stereotactic body radiotherapy, and all types of brachytherapy). Residents of mountainous and less densely populated areas faced longer travel times to the nearest radiotherapy unit. The availability of resources within the closest radiotherapy unit was independent of travel ","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 3","pages":"Article 104835"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148623002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}